

Francesca Sperati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5285652/publications.pdf>

Version: 2024-02-01

101
papers

3,088
citations

172207

29
h-index

205818

48
g-index

104
all docs

104
docs citations

104
times ranked

4899
citing authors

#	ARTICLE	IF	CITATIONS
1	Parenteral anticoagulation in ambulatory patients with cancer. The Cochrane Library, 2023, 2023, CD006652.	1.5	42
2	Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2023, 2023, CD006650.	1.5	65
3	Diagnostic Accuracy of Contrast-Enhanced, Spectral Mammography (CESM) and 3T Magnetic Resonance Compared to Full-Field Digital Mammography plus Ultrasound in Breast Lesions: Results of a (Pilot) Open-Label, Single-Centre Prospective Study. Cancers, 2022, 14, 1351.	1.7	2
4	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death and Differentiation, 2021, 28, 2060-2082.	5.0	19
5	The efficacy of balneotherapy, mud therapy and spa therapy in patients with osteoarthritis: an overview of reviews. International Journal of Biometeorology, 2021, 65, 1255-1271.	1.3	11
6	Instrumental evaluation of skin barrier function and clinical outcomes during dupilumab treatment for atopic dermatitis: An observational study. Skin Research and Technology, 2021, 27, 810-813.	0.8	10
7	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. Cancers, 2021, 13, 1957.	1.7	8
8	KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy. Journal of Thoracic Oncology, 2021, 16, 2065-2077.	0.5	28
9	Multiparametric MRI Evaluation of Oropharyngeal Squamous Cell Carcinoma. A Mono-Institutional Study. Journal of Clinical Medicine, 2021, 10, 3865.	1.0	6
10	Coping Style in Glioma Patients and Their Caregiver: Evaluation During Disease Trajectory. Frontiers in Neurology, 2021, 12, 709132.	1.1	4
11	Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. The Cochrane Library, 2021, 2021, CD014739.	1.5	4
12	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. The Cochrane Library, 2021, 2021, CD006466.	1.5	2
13	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2021, 2021, CD006649.	1.5	4
14	Electronic Test of Competence Administration: Qualitative Evaluation of Students's Satisfaction on Telematic Platform a Cross Sectional Study. Advances in Intelligent Systems and Computing, 2020, , 47-54.	0.5	6
15	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Annals of Oncology, 2020, 31, 1746-1754.	0.6	140
16	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13
17	Quality of life and disability of chronic non-cancer pain in adults patients attending pain clinics: A prospective, multicenter, observational study. Applied Nursing Research, 2020, 56, 151332.	1.0	14
18	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. Clinical Breast Cancer, 2020, 20, e761-e770.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Correlation between histogram-based DCE-MRI parameters and 18F-FDG PET values in oropharyngeal squamous cell carcinoma: Evaluation in primary tumors and metastatic nodes. <i>PLoS ONE</i> , 2020, 15, e0229611.	1.1	7
20	Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e199.	1.7	1
21	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. <i>The Cochrane Library</i> , 2019, 2019, CD006649.	1.5	26
22	Anticoagulation for people with cancer and central venous catheters. <i>The Cochrane Library</i> , 2019, 2019, CD006468.	1.5	28
23	Anticoagulation for perioperative thromboprophylaxis in people with cancer. <i>The Cochrane Library</i> , 2019, 2019, CD009447.	1.5	15
24	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 144, 211-216.	1.4	3
25	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1924-1934.	0.5	60
26	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	2
27	Intravoxel incoherent motion diffusion-weighted imaging for oropharyngeal squamous cell carcinoma: Correlation with human papillomavirus Status. <i>European Journal of Radiology</i> , 2019, 119, 108640.	1.2	12
28	Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. <i>Journal of Translational Medicine</i> , 2019, 17, 131.	1.8	17
29	The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	2.1	11
30	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. <i>Gut</i> , 2018, 67, 903-917.	6.1	64
31	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	2.0	17
32	Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. <i>Journal of Cellular Physiology</i> , 2018, 233, 2572-2580.	2.0	11
33	Lacosamide on background eeg activity in brain tumor-related epilepsy patients: A case series study. <i>Brain and Behavior</i> , 2018, 8, e01067.	1.0	6
34	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 247.	1.8	6
35	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	2.1	12
36	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	1.8	13

#	ARTICLE	IF	CITATIONS
37	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	2.3	30
38	Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	1.1	12
39	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	1.5	22
40	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 2246-2252.	2.0	9
41	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	1.6	16
42	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017, 7, 8078.	1.6	14
43	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>The Cochrane Library</i> , 2017, 12, CD006466.	1.5	17
44	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 143.	3.5	4
45	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	1.2	4
46	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	2.1	30
47	Relationship between diffusion parameters derived from intravoxel incoherent motion MRI and perfusion measured by dynamic contrast-enhanced MRI of soft tissue tumors. <i>NMR in Biomedicine</i> , 2016, 29, 6-14.	1.6	30
48	A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 124.	3.5	66
49	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016, 6, 35121.	1.6	6
50	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 62.	3.5	24
51	Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia. <i>Cognitive Neurodynamics</i> , 2016, 10, 185-188.	2.3	2
52	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	1.1	11
53	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016, 7, 43188-43198.	0.8	35
54	Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. <i>Journal of Cellular Physiology</i> , 2015, 230, 1708-1712.	2.0	5

#	ARTICLE	IF	CITATIONS
55	ATM kinase sustains HER2 tumorigenicity in breast cancer. <i>Nature Communications</i> , 2015, 6, 6886.	5.8	50
56	TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. <i>Oncogene</i> , 2015, 34, 681-690.	2.6	287
57	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	0.8	14
58	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. <i>The Cochrane Library</i> , 2014, , CD006649.	1.5	52
59	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. <i>The Cochrane Library</i> , 2014, , CD006650.	1.5	152
60	Weight of epilepsy in brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2014, 118, 385-393.	1.4	37
61	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		9
62	Anticoagulation for people with cancer and central venous catheters. <i>The Cochrane Library</i> , 2014, , CD006468.	1.5	41
63	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		13
64	Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. <i>The Cochrane Library</i> , 2014, , CD009447.	1.5	32
65	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	0.8	11
66	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014, 5, 9619-9625.	0.8	35
67	External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 58.	3.5	9
68	Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. <i>Breast Cancer Research</i> , 2013, 15, R46.	2.2	31
69	Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>PLoS ONE</i> , 2013, 8, e69269.	1.1	45
70	Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. <i>Annals of Oncology</i> , 2012, 23, 1838-1845.	0.6	25
71	Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. <i>Epileptic Disorders</i> , 2012, 14, 388-397.	0.7	26
72	Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. <i>Journal of Neuro-Oncology</i> , 2012, 106, 651-656.	1.4	43

#	ARTICLE	IF	CITATIONS
73	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006466.		13
74	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2011, , CD006650.		30
75	The Validity and Sensitivity to Change of the Spanish Self-Administered Version of the Chronic Respiratory Questionnaire (CRQ-SAS). Archivos De Bronconeumologia, 2011, 47, 343-349.	0.4	14
76	Using alternative statistical formats for presenting risks and risk reductions. The Cochrane Library, 2011, , CD006776.	1.5	140
77	Anticoagulation for patients with cancer and central venous catheters. , 2011, , CD006468.		22
78	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		16
79	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		8
80	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		21
81	Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. , 2011, , CD009447.		16
82	Anticoagulation for patients with cancer and central venous catheters. , 2011, , CD006468.		18
83	Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. Journal of Neuro-Oncology, 2011, 104, 205-214.	1.4	87
84	Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. Journal of Neurology, 2011, 258, 2100-2104.	1.8	61
85	Framing of health information messages. The Cochrane Library, 2011, , CD006777.	1.5	119
86	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2010, , CD006466.		9
87	Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. Journal of Neuro-Oncology, 2010, 98, 109-116.	1.4	38
88	An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation. Health and Quality of Life Outcomes, 2010, 8, 26.	1.0	28
89	Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurological Sciences, 2009, 30, 353-359.	0.9	40
90	The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clinical Endocrinology, 2009, 70, 661-670.	1.2	30

#	ARTICLE	IF	CITATIONS
91	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. Journal of Experimental and Clinical Cancer Research, 2009, 28, 135.	3.5	16
92	Thromboprophylaxis for patients with cancer and central venous catheters. Cancer, 2008, 112, 2483-2492.	2.0	81
93	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cancer, 2008, 113, 1685-1694.	2.0	33
94	Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. Journal of Experimental and Clinical Cancer Research, 2008, 27, 21.	3.5	51
95	Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Prostate Cancer Risk: Results From a Case-Control Study. Urology, 2008, 72, 183-187.	0.5	15
96	Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Thromboprophylaxis in Patients With Cancer<subtitle>A Systematic Review and Meta-analysis</subtitle>. Archives of Internal Medicine, 2008, 168, 1261.	4.3	75
97	Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. , 2008, , CD006650.		21
98	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2008, , CD006649.		9
99	Extended perioperative thromboprophylaxis in patients with cancer. Thrombosis and Haemostasis, 2008, 100, 1176-1180.	1.8	63
100	Oral anticoagulation for prolonging survival in patients with cancer. , 2007, , CD006466.		25
101	Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. , 2007, , CD006468.		28